Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
PMVP 
Pmv Pharmaceuticals Inc (PMVP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/19/2025: PMVP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.6
1 Year Target Price $7.6
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.25% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/19/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 65.98M USD | Price to earnings Ratio - | 1Y Target Price 7.6 |
Price to earnings Ratio - | 1Y Target Price 7.6 | ||
Volume (30-day avg) 5 | Beta 1.64 | 52 Weeks Range 0.81 - 1.84 | Updated Date 12/21/2025 |
52 Weeks Range 0.81 - 1.84 | Updated Date 12/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.02% | Return on Equity (TTM) -51.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -62070674 | Price to Sales(TTM) - |
Enterprise Value -62070674 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.24 | Shares Outstanding 53211507 | Shares Floating 41147926 |
Shares Outstanding 53211507 | Shares Floating 41147926 | ||
Percent Insiders 3.3 | Percent Institutions 69.83 |
Upturn AI SWOT
Pmv Pharmaceuticals Inc
Company Overview
History and Background
Pmv Pharmaceuticals Inc. was founded in [Founding Year, if available]. Information regarding specific milestones and its evolution is not readily available in public domain for a private entity or a company with limited public disclosure. As such, a detailed historical overview cannot be provided.
Core Business Areas
- Pharmaceutical Research and Development: Focuses on the discovery, development, and potential commercialization of novel pharmaceutical products. This typically involves pre-clinical and clinical trials to assess safety and efficacy of new drug candidates.
Leadership and Structure
Information on the specific leadership team and organizational structure of Pmv Pharmaceuticals Inc. is not publicly disclosed. As a private entity or a company with limited public filings, detailed internal governance is not available.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The pharmaceutical industry is a complex and highly regulated sector characterized by significant investment in research and development, long product development cycles, and intense competition. Key trends include advancements in biotechnology, personalized medicine, and increasing global healthcare demands.
Positioning
Pmv Pharmaceuticals Inc.'s specific positioning within the market is not publicly discernible due to limited public information. Its success would depend on the efficacy, safety, and market adoption of its pipeline products.
Total Addressable Market (TAM)
The Total Addressable Market for pharmaceuticals is vast, encompassing numerous therapeutic areas. Without knowledge of Pmv Pharmaceuticals Inc.'s specific drug candidates, its position relative to this TAM cannot be determined.
Upturn SWOT Analysis
Strengths
- Potential for innovative drug discovery.
- Agility as a potentially smaller or private entity.
Weaknesses
- Limited public financial data hinders comprehensive analysis.
- Lack of established brand recognition and market presence (if early stage).
- High risk associated with pharmaceutical R&D.
Opportunities
- Addressing unmet medical needs through novel therapies.
- Strategic partnerships and collaborations.
- Emerging markets for pharmaceutical products.
Threats
- Regulatory hurdles and lengthy approval processes.
- Intense competition from established pharmaceutical giants and smaller biotechs.
- Patent expirations and generic competition for successful drugs.
- Adverse clinical trial results.
Competitors and Market Share
Key Competitors
Competitive Landscape
Without specific information on Pmv Pharmaceuticals Inc.'s product pipeline and stage of development, its competitive landscape is too broad to define. It would likely compete with other pharmaceutical and biotechnology companies developing similar therapeutic agents.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends for Pmv Pharmaceuticals Inc. are not publicly documented.
Future Projections: Future growth projections are speculative due to the absence of public data and analyst coverage.
Recent Initiatives: Specific recent strategic initiatives undertaken by Pmv Pharmaceuticals Inc. are not publicly disclosed.
Summary
Pmv Pharmaceuticals Inc.'s public profile is limited, making a comprehensive analysis challenging. The company's success hinges on its ability to develop and successfully bring innovative pharmaceutical products to market, navigating significant regulatory and competitive hurdles. Lack of transparency in financial performance and strategic direction necessitates caution for potential investors or partners.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Publicly available company information.
- General industry analysis of the pharmaceutical sector.
Disclaimers:
This analysis is based on limited publicly available information for Pmv Pharmaceuticals Inc. As such, it may not be exhaustive or entirely accurate. This JSON output is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pmv Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2020-09-25 | Co-Founder, CEO, President & Director Dr. David H. Mack Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 47 | Website https://www.pmvpharma.com |
Full time employees 47 | Website https://www.pmvpharma.com | ||
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.